News

Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.
Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
The stock's rise snapped a three-day losing streak.
Morgan Stanley Remains a Hold on Vertex Pharmaceuticals (VRTX)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Vertex Pharmaceuticals price target raised to $462 from $459 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...